|
1) Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. J Clin Invest. 2007; 117: 2067-74
|
|
|
|
2) Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005; 435: 1267-70
|
|
|
|
|
|
3) Roeder I, Horn M, Glauche I, et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006; 12: 1125-6
|
|
|
|
|
|
4) Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108: 1809-20
|
|
|
|
|
|
5) Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors—review and recommendations for “harmonizing" current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37
|
|
|
|
|
|
6) Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-17
|
|
|
|
|
|
7) Baccarani M, Guilhot F, Larson RA, et al. Outcomes by cytogenetic and molecular response at 12 and 18 months of imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) in the IRIS Trial. Blood. 2006; 108: 606a
|
|
|
|
|
|
8) Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology. 2006; : 211-8
|
|
|
|
|
|
9) National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-ver 2. 2007. Chronic Myelogenous Leukemia. http://www.nccn.org
|
|
|
|
|
|
10) 日本造血細胞移植学会全国データ集計事務局. 日本造血細胞移植学会平成17年度全国調査報告書. 2006
|
|
|
|
|
|
11) Jane F. Apperley JF. Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. Hematology. 2006; : 226-32
|
|
|
|
|
|
12) Oehler VG, Gooley T, Synder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007; 109: 1782-9
|
|
|
|
|
|
13) Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure. Blood. 2006; 108: 1421-3
|
|
|
|
|
|
14) Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006; 91: 452-9
|
|
|
|
|
|
15) Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003; 101: 441
|
|
|
|
|
|
16) Larson RA, Druker BJ, Guilhot F, et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. An Analysis of IRIS Study Data. Blood. 2006; 108: 131a
|
|
|
|
|
|
17) Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007; 109: 3496-9
|
|
|
|
|
|
18) Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103: 2873-8
|
|
|
|
|
|
19) Aoki E. Hagop Kantarjian, O'Brien S, et al. High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) CML. Blood. 2006; 108: 608a
|
|
|
|
|
|
20) Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007; 109: 58-60
|
|
|
|
|
|
21) Michael J. Mauro MJ. Defining and managing imatinib resistance. Hematology. 2006; : 219-25
|
|
|
|
|
|
22) Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004; 104: 2926-32
|
|
|
|
|
|
23) Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354: 2531-41
|
|
|
|
|
|
24) Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109: 2303-9
|
|
|
|
|
|
25) Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia-chromosome positive ALL. N Engl J Med. 2006; 354: 2542-51
|
|
|
|
|
|
26) Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib resistant BCR-ABL＋ neoplastic cells. Cancer Res. 2006; 66: 11314-22
|
|
|
|
|
|
27) Cortes J, Kantarjian HM, Baccarani M, et al. A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph＋) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia relapsed, refractory or intolerant of imatinib. Blood. 2006; 108: 54a
|
|
|
|
|
|
28) Giles FJ, Cortes JE, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007; 109: 500-2
|
|
|
|
|
|
29) Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high dose imatinib for chronic phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase II trial. Blood. 2007; 109: 5143-50
|
|
|
|
|